Logo image of AB.PA

AB SCIENCE SA (AB.PA) Stock Fundamental Analysis

EPA:AB - Euronext Paris - Matif - FR0010557264 - Common Stock - Currency: EUR

1.14  -0.02 (-1.89%)

Fundamental Rating

1

Overall AB gets a fundamental rating of 1 out of 10. We evaluated AB against 51 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AB have multiple concerns. AB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AB had negative earnings in the past year.
In the past year AB had a positive cash flow from operations.
In the past 5 years AB always reported negative net income.
AB had negative operating cash flow in 4 of the past 5 years.
AB.PA Yearly Net Income VS EBIT VS OCF VS FCFAB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -33.79%, AB is doing worse than 82.35% of the companies in the same industry.
Industry RankSector Rank
ROA -33.79%
ROE N/A
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AB.PA Yearly ROA, ROE, ROICAB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

With an excellent Gross Margin value of 116.42%, AB belongs to the best of the industry, outperforming 98.04% of the companies in the same industry.
AB's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for AB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 116.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
AB.PA Yearly Profit, Operating, Gross MarginsAB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AB has more shares outstanding than it did 1 year ago.
AB has more shares outstanding than it did 5 years ago.
AB has a worse debt/assets ratio than last year.
AB.PA Yearly Shares OutstandingAB.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AB.PA Yearly Total Debt VS Total AssetsAB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -18.11, we must say that AB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -18.11, AB is not doing good in the industry: 84.31% of the companies in the same industry are doing better.
AB has a debt to FCF ratio of 50.12. This is a negative value and a sign of low solvency as AB would need 50.12 years to pay back of all of its debts.
The Debt to FCF ratio of AB (50.12) is worse than 64.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 50.12
Altman-Z -18.11
ROIC/WACCN/A
WACC7.01%
AB.PA Yearly LT Debt VS Equity VS FCFAB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

A Current Ratio of 0.71 indicates that AB may have some problems paying its short term obligations.
The Current ratio of AB (0.71) is worse than 86.27% of its industry peers.
AB has a Quick Ratio of 0.71. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.
AB has a worse Quick ratio (0.70) than 74.51% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.7
AB.PA Yearly Current Assets VS Current LiabilitesAB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

AB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.17%, which is quite impressive.
AB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.52%.
The Revenue has been decreasing by -7.36% on average over the past years.
EPS 1Y (TTM)40.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.41%
Revenue 1Y (TTM)10.52%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-1.92%

3.2 Future

Based on estimates for the next years, AB will show a small growth in Earnings Per Share. The EPS will grow by 3.59% on average per year.
AB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.96% yearly.
EPS Next Y7.32%
EPS Next 2Y3.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.94%
Revenue Next 2Y9.96%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AB.PA Yearly Revenue VS EstimatesAB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
AB.PA Yearly EPS VS EstimatesAB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AB.PA Price Earnings VS Forward Price EarningsAB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

AB's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. AB is more expensive than 64.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 182.92
EV/EBITDA N/A
AB.PA Per share dataAB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.59%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AB SCIENCE SA

EPA:AB (6/19/2025, 7:00:00 PM)

1.14

-0.02 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13
Earnings (Next)09-29 2025-09-29
Inst Owners0.14%
Inst Owner ChangeN/A
Ins Owners34.34%
Ins Owner ChangeN/A
Market Cap67.68M
Analysts86.67
Price Target3.53 (209.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.87%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 63.14
P/FCF 182.92
P/OCF 128.92
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)0.01
FCFY0.55%
OCF(TTM)0.01
OCFY0.78%
SpS0.02
BVpS-0.4
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.79%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 116.42%
FCFM 34.51%
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
F-Score6
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 50.12
Debt/EBITDA N/A
Cap/Depr 23.24%
Cap/Sales 14.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.7
Altman-Z -18.11
F-Score6
WACC7.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)39.08%
Cap/Sales(5y)35.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.41%
EPS Next Y7.32%
EPS Next 2Y3.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.52%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-1.92%
Revenue Next Year10.94%
Revenue Next 2Y9.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y102.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y103.11%
OCF growth 3YN/A
OCF growth 5YN/A